Mirae Asset Global Investments Co., Ltd. Denali Therapeutics Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $28 Billion
- Q2 2025
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 5,612 shares of DNLI stock, worth $96,807. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,612
Previous 4,859
15.5%
Holding current value
$96,807
Previous $66,000
18.18%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding DNLI
# of Institutions
248Shares Held
135MCall Options Held
148KPut Options Held
15.4K-
Black Rock Inc. New York, NY13.2MShares$227 Million0.01% of portfolio
-
Baillie Gifford & CO12MShares$206 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$204 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.58MShares$114 Million0.01% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL6.26MShares$108 Million0.02% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.31B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...